Archived
This content is available here strictly for research, reference, and/or recordkeeping and as such it may not be fully accessible. If you work or study at University of Kentucky and would like to request an accessible version, please use the SensusAccess Document Converter.
Date Available
9-13-2014
Year of Publication
2012
Document Type
Master's Thesis
Degree Name
Master of Science (MS)
College
Arts and Sciences
Department/School/Program
Chemistry
Faculty
Dr. Edith Glazer
Faculty
Dr. John Anthony
Faculty
Dr. David Atwood
Abstract
Ruthenium complexes show promise as light activated photodynamic therapy (PDT) prodrugs. Strained octahedral complexes were synthesized that produce a cytotoxic species upon light activation. pUC19 DNA damage in vitro experiments were carried out to determine the type of damage observed. In vivo cell experiments were carried out on the non-small lung cancer A549 cell line to determine the phototherapeutic window of the synthesized complexes. One mechanism of drug resistance via elevated levels of glutathione was addressed through in vitro binding studies carried out with UV-Vis spectroscopy and in vivo glutathione titrations in the A549 cell line. Several complexes were shown to be potential PDT agents with light-activated activities greater than cisplatin and 10-100 fold lower dark toxicities.
Recommended Citation
Howerton, Brock S., "Design, Synthesis, and Anticancer Activity of Ruthenium Complexes" (2012). Theses and Dissertations--Chemistry. 10.
https://uknowledge.uky.edu/chemistry_etds/10
